A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors

被引：0
|
作者：
Hansen, M
Gimsing, P
Rasmussen, A
Jensen, PB
Knudsen, LM
机构：
[1] Rigshosp, DK-2100 Copenhagen, Denmark
[2] Topotarget AS, Copenhagen, Denmark
[3] Herlev Univ Hosp, Copenhagen, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225S / 225S
页数：1
相关论文
共 50 条
  • [41] Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates
    Katherine E. Warren
    Cindy McCully
    Henrik Dvinge
    Jette Tjørnelund
    Maxwell Sehested
    Henri S. Lichenstein
    Frank M. Balis
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 433 - 437
  • [42] A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
    Northfelt, D. W.
    Marschke, R. F., Jr.
    Bonnem, E.
    Ooi, C. E.
    Gerwien, R.
    Hawthorne, T.
    Clarke, A.
    Buhl-Jensen, P.
    Von Hoff, D.
    Grem, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase II trial of the histone deacetylase inhibitor Belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A trial of the PMH Phase II Consortium
    Mackay, Helen J.
    Hirte, Hal
    Covens, Al
    MacAlpine, Katrina
    Wang, Lisa
    Tsao, Ming
    Pan, James
    Zweibel, James
    Oza, Amit M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3388S - 3388S
  • [44] A phase I safety, pharmacokinetic and pharmacodynamic study of intravenously administered PXD101 plus carboplatin or paclitaxel or both in patients with advanced solid tumors
    Lassen, U.
    Sorensen, M.
    De Bono, J. S.
    Molife, R.
    Vidal, L.
    Settatree, S.
    Seiden, M. V.
    Li, S. X.
    Jensen, P. B.
    EJC SUPPLEMENTS, 2006, 4 (12): : 111 - 111
  • [45] A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
    Gimsing, Peter
    Hansen, Mads
    Knudsen, Lene M.
    Knoblauch, P.
    Christensen, Ib Jarle
    Ooi, Chean Eng
    Buhl-Jensen, Peter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 81 (03) : 170 - 176
  • [46] A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial
    Mackay, H.
    Hirte, H. W.
    Covens, A.
    MacAlpine, K.
    Wang, L.
    Tsao, M. S.
    Pan, J.
    Zwiebel, J. A.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Phase I clinical, pharmacokinetic, and pharmacodynamic study of CG200745, a histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.
    Kim, Kyu-Pyo
    Hong, Yong Sang
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Bae, Kyun-Seop
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
    Northfelt, D.
    Ooi, C. E.
    Gerwien, R.
    Hawthorne, T.
    Clarke, A.
    Jones, S.
    Rodriguez, G.
    Buhl-Jensen, P.
    Von Hoff, D.
    Grem, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 57 - 57
  • [49] PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors
    Li, Jingyao
    Li, Xiaoyang
    Wang, Xue
    Hou, Jinning
    Zang, Jie
    Gao, Shuai
    Xu, Wenfang
    Zhang, Yingjie
    CHEMICAL BIOLOGY & DRUG DESIGN, 2016, 88 (04) : 574 - 584
  • [50] A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors
    Rowinsky, EK
    Pacey, S
    Patnaik, A
    O'Donnell, A
    Mita, MM
    Atadja, P
    Peng, B
    Dugan, M
    Scott, JW
    De Bono, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 200S - 200S
12345